In-vitro fertilization is a type of assisted reproductive technology that helps women in conceiving. The Asia Pacific IVF services market, valued at $3.0 billion in 2015, is estimated to reach $7.1 billion by 2022. Delayed pregnancy in women is one of the major driving factors of the embryo transfer market, as the chances of conceiving lowers with age. Success rate of getting pregnant with embryo transfer technique reduces with increase in age. Other driving factors of the embryo transfer market are rise in infertility rate due to rise in stress levels, change in life style and fertility related diseases. Globally, around 15% of the couples faces infertility issues in which males contribute to 20-30% of the overall cases.

The major limiting factors of this market are the cost involved and lower success rates in the treatment. Patients may not conceive in the first cycle of embryo transfer procedure. Patients have to undergo many cycles to achieve pregnancy, and this adds to the overall cost. The average cost of this procedure is approximately $3,000- $8,000. This acts as a major limitation, in adoption of the technique, for people with low income. Another challenge is the low level of awareness in the developing economies such as Nigeria, India, Indonesia among others. Awareness can be created through medical tourism and availability of low cost embryo transfer treatments. The companies profiled in this report include Vitrolife AB, Cooper Surgical. Inc., Cook Medicals, Thermo Fisher Scientific, Irvine Scientific Inc., Genea Biomedx, Oxford Gene Technology, Auxogyn Inc., EMD Serono Inc. and Ovascience Inc.

KEY BENEFITS FOR STAKEHOLDERS:

This report provides an in-depth analysis of the Asia-Pacific IVF market across twelve major countries along with cross sectional analysis of the total number of IVF cycles performed and the total revenue generated during the forecast period.The report includes the strategies adopted by various IVF clinics and hospitals across major countries to capitalize on the latent opportunities in the Asia-Pacific IVF market.This report comprehensively analyzes the market scenario across different countries in the Asia-Pacific region.The projections in this report are made by analyzing the current market trends and highlighting the market potential, in terms of value and volume, from 2015 to 2022.Extensive analysis of the market is conducted by following the key product positioning and monitoring the top contenders.

FEATURED COMPANIES

Asia-Pacific In-vitro Fertilization (IVF) Services Market Report, forecasts that the Asia-Pacific Market is expected to reach $7 billion by 2022, growing at a CAGR of 13.3% from 2016 to 2022. The fresh cycle (non-donor) segment accounted for approximately three-fourths share in 2015 and is expected to maintain its dominance during the forecast period.

Changing lifestyle conditions, reduced conceiving rates in women above 40 years, delay in pregnancy in women suffering from gynecological conditions, and fertility disorders followed by favorable reimbursement scenario and delayed parenthood opted by couples due to professional and financial constraints are some of the major factors that drive the market growth. The Asia-Pacific IVF market is estimated to grow at a CAGR of 13.3% during 2016-2022.

The rapidly growing geriatric population has been a major concern for the government in most of the countries in the Asia-Pacific region. Several countries, such as Vietnam, Cambodia, and Philippines, have fertility rates of 2 births per woman, which is below the average rate of 2.1 births per woman. These countries are keen on boosting their fertility rates to maintain balance between new born and geriatric populations. Indonesia in particular had a fertility rate of 2.1 and geriatric population of about 5% of the total population in 2015. According to AgeingAsia.org, this number is anticipated to reach 74 million by 2050. Korea, which had a fertility rate of 1.25 in 2014, has announced financial support for infertility treatment. Similarly, Singapore, with fertility rate of 0.80 in 2014, has increased the subsidy for treatment to 75% of the treatment cost. These factors have been instrumental in driving the growth of the Asia-Pacific embryo transfer market.

In the end user segment, fertility clinics accounted for major share of the Asia-Pacific IVF market in 2015, and is projected to maintain this trend throughout the forecast period. The rise can be attributed to rise in the number of fertility clinics as well as the availability of wide range of fertility treatments under one roof coupled with government reimbursements. Fertility clinics are followed by hospitals in terms of revenue generation and together with fertility clinics they occupy approximately four-fifth share of the overall Asia-Pacific market.

India is forecast to be the fastest growing country in Asia-Pacific IVF market, growing at a CAGR of 16.6% from 2016 to 2022 in terms of revenue.

In 2015, China and Japan collectively accounted for approximately two-thirds share of the Asia-Pacific IVF market volume.

Fresh cycle (non-donor) would be the highest revenue generating segment followed by Thawed IVF cycle (non-donor) during 2016-2022.

Thawed IVF cycle (non-donor) will be the fastest growing segment in Vietnam during 2016-2022 growing at a CAGR of 8.2% in terms of volume.

Japan is the highest revenue-generating region in 2015, owing to the widespread adoption of IVF techniques. However, India is expected to grow rapidly during the forecast period, owing to the growth in cost per cycle due to increasing sophistications of procedures and advancements in technology.